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LETTERS TO THE EDITOR
On the safety of intravenous iron, evidence trumps
conjecture
Anemia is one of the world’s most common disorders. In
2010, global anemia prevalence was 32.9%, affecting over
2.2 billion people, and iron deficiency the most common of
the causes.1 Oral iron, while inexpensive and effective
when taken and tolerated, is frequently associated with
unpleasant gastrointestinal side-effects, resulting in high
rates of non-adherence. Furthermore, in conditions such
as inflammatory bowel disease, end-stage renal disease,
heavy uterine bleeding, hereditary hemorrhagic telangiectasia, and following major and bariatric surgery, oral iron
may be ineffective due to its inability to keep up with losses
or may be harmful by worsening the underlying pathology
or by causing significant gastrointestinal side-effects. Under
these circumstances, intravenous iron administration is the
repletion route of choice. Currently, five formulations are
available in the United States and six in Europe. Based on
the overwhelming amount of published evidence, intravenous iron is nearly universally effective, with serious
adverse events being very rare, estimated to be less than
1:200,000 administrations.2 Nonetheless, there is an ongoing prejudice against the use of parenteral iron largely based
on experience with earlier preparations that are no longer
available and which were associated with unacceptably
high rates of anaphylactic reactions. Adding to these concerns is the use of spontaneous reporting of serious adverse
events, a proscribed method of determining relative safety
profiles of different formulations,3 and corroborated by a
recent guidance document by the European Medicines
Agency stating post-marketing spontaneous reports "cannot be used to detect any differences in the safety profile of
the different iron medicines”.4
Therefore, the seventeen co-authors of this commentary
wish to challenge the conclusions drawn in a recent
Prescrire publication, which makes recommendations
based on inferences that are inaccurate and clinically
imprudent.5
In a recent criticism of the use of intravenous iron and a
warning against one product, ostensibly less safe than others, the authors omitted all prospective and intrainstitutional observational studies that have come to the opposite
conclusion (see below).6,7 An example is found in the concluding paragraph: “Given the risk of serious hypersensitivity reactions as well as other adverse effects, the use of
intravenous iron-containing products should be limited to
situations in which the benefits clearly outweigh the harm.
Iron sucrose is the best choice, as other products do not
have a more favorable harm-benefit balance. The decision
to keep iron dextran on the market is absurd: it protects the
manufacturer while exposing patients to unnecessary
risks”. In contradistinction, an examination of published
evidence suggests the above statements are simply incorrect. Below we highlight this evidence.
Shortly after recombinant erythropoietin was approved
for correction of anemia in patients on dialysis, it became
apparent that intravenous iron was necessary for an optimal erythropoietic response. High molecular weight iron
dextran (HMWID, Imferon®), which is no longer available,
was the only formulation used at first. While infrequent
serious reactions were observed, safety concerns were
raised. Then, in 1991, Imferon® was removed from market,
but serendipitously at the same time, low molecular weight
iron dextran (LMWID, INFeD® in the United States and

CosmoFer® in Europe) was approved for use. The literature
is rife with safety and efficacy reports, and serious adverse
events with LMWID are extremely rare. It was not until
1996, when a HMWID (Dexferrum®), which is also no
longer available, was released, that serious adverse events
became frequent; numerous publications support this
view.8 With HMWID now withdrawn from the market,
there is no credible evidence supporting either increased
efficacy or decreased safety with any of the remaining
available formulations compared to any other. As a result,
the US FDA wrote a letter to the American distributors of
iron sucrose, which is now in the public domain, ordering
them to remove all advertising claiming any safety advantage with iron sucrose.
Three prospective studies, a meta-analysis and an intrainstitutional observational study at the Harvard Medical
School hospitals6,7 report no significant efficacy or safety
differences. A comparison of ferric carboxymaltose and
LMWID in second and third trimester gravidas reported
safety and efficacy without serious adverse events in either
group.9 Supporting their conclusions in a single institution
observational study using a prospective model for the integrated safety analysis, 1266 total dose infusions (1000 mg
in 1 h) of low molecular weight iron dextran were given to
888 patients, 162 of whom were pregnant, intolerant of
oral iron, or in whom oral iron was ineffective or contraindicated.10 No serious adverse events were observed.
Low molecular weight iron dextran is the formulation currently being used for the first prospective study of intravenous iron in the second or third trimester of pregnancy in
the US under an FDA IND (#114696). In a preliminary
analysis of 57 of 60 planned subjects having completed
study treatment to date, no serious adverse events have
been observed. It should be noted that the total number of
subjects included in these studies is small, and important
adverse effects and relative differences in adverse events
could be present that are not reflected in the studies.
In a prospective, controlled, randomized trial of 162
patients, comparing iron sucrose and ferumoxytol in
patients with chronic kidney disease, the authors reported
no difference in safety or efficacy.11 The only prospective
trial to report a significant safety difference between any of
the formulations compared the now unavailable HMWID
to ferric carboxymaltose and erroneously concluded, without differentiating the high and low molecular weight formulations, that ferric carboxymaltose had a safety advantage over iron dextran.12 Corroborating data were recently
published in a large meta-analysis of studies carried out in
thousands of subjects who received intravenous iron.13
In an editorial accompanying the article, Prescrire reported that “there is no advantage to the use of iron dextran
over iron sucrose and the risks of using iron dextran far outweigh the benefits”. Not only is the statement without evidence to support it, but a replacement dose of intravenous
iron sucrose requires four or five clinical visits compared to
one visit with an infusion of 1000 mg of LMWID (a commonly used method approved in Europe but still off label in
the US). The same advantage can be achieved with ferric
carboxymaltose (approved as 1000 mg in 15 min in Europe
and 750 mg in the US), iron isomaltoside (Europe only),
and ferumoxytol (approval limited to 510 mg per visit).
Pre-medication with antihistamines is frequently administered without any data supporting their use. There are
even published data suggesting that the majority of adverse
events seen with intravenous iron, when intravenous
diphenhydramine is used as pre-medication, are due to the
pre-medication and mistakenly attributed to the intra-
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venous iron.14 Antihistamines can cause flushing, hypotension, somnolence, and supraventricular tachycardia,
prompting inappropriate intervention and the conversion
of a minor reaction to a severe one. In contrast, there is a
syndrome occurring in approximately 1:200 patients, consisting of arthralgias, myalgias or flushing, without associated hypotension, tachycardia, tachypnea, wheezing, stridor or periorbital edema. No intervention is necessary.15
After symptoms abate, re-challenge is appropriate. In the
rare patient who reacts twice, the iron formulation should
be changed. Antihistamines are inappropriate since measured tryptase levels after these reactions have always been
normal.16 While post-marketing, spontaneous adverse
event reporting can provide useful and important information, one simply cannot determine relative safety among
formulations. Without head-to-head trials, such conclusions lack validity.
Parenteral iron is not just ‘superior’, it is a necessity since
oral iron is ineffective in a number of clinical settings.
Overstating the avoidance of intravenous iron is not only
counterproductive but potentially harmful. Limiting its use
will dramatically increase erythropoietin usage as well as
transfusions and their associated complications. Essentially,
all interpretable evidence supports the equivalent efficacy
and safety of all of the current intravenous iron formulations. If minor infusion reactions occur with one formulation, switching to another is appropriate and safe.
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